Ampicillin compared with penicillin and chloramphenicol combined in the treatment of bacterial meningitis. 1972

N I Girgis, and M W Yassin, and W R Sanborn, and R E Burdick, and H A el-Ela, and D C Kent, and K Sorensen, and I M Nabil

UI MeSH Term Description Entries
D008297 Male Males
D008581 Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6) Pachymeningitis,Meningitides,Pachymeningitides
D008583 Meningitis, Haemophilus Infections of the nervous system caused by bacteria of the genus HAEMOPHILUS, and marked by prominent inflammation of the MENINGES. HAEMOPHILUS INFLUENZAE TYPE B is the most common causative organism. The condition primarily affects children under 6 years of age but may occur in adults. Haemophilus influenzae Meningitis Type B,Hemophilus influenzae Meningitis Type B,Meningitis, Haemophilus influenzae Type F,Meningitis, Haemophilus parainfluenzae,Meningitis, Hemophilus,Meningitis, Hemophilus influenzae Type F,Meningitis, Hemophilus influenzae, Type B,Meninigitis, HiB,Type B Haemophilus influenzae Meningitis,Type B Hemophilus influenzae Meningitis,Haemophilus Meningitides,Haemophilus Meningitis,Haemophilus parainfluenzae Meningitides,Haemophilus parainfluenzae Meningitis,Hemophilus Meningitides,Hemophilus Meningitis,HiB Meninigitis,Meningitides, Haemophilus,Meningitides, Haemophilus parainfluenzae,Meningitides, Hemophilus
D008585 Meningitis, Meningococcal A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8) Meningitis, Neisseria,Neisseria Meningitis,Meningitis, Meningococcal, Serogroup A,Meningitis, Meningococcal, Serogroup B,Meningitis, Meningococcal, Serogroup C,Meningitis, Meningococcal, Serogroup W-135,Meningitis, Meningococcal, Serogroup W135,Meningitis, Meningococcal, Serogroup Y,Meningitis, Meningococcic,Meningococcal Meningitis, Serogroup A,Meningococcal Meningitis, Serogroup B,Meningococcal Meningitis, Serogroup C,Meningococcal Meningitis, Serogroup W-135,Meningococcal Meningitis, Serogroup W135,Meningococcal Meningitis, Serogroup Y,Serogroup A Meningococcal Meningitis,Serogroup B Meningococcal Meningitis,Serogroup C Meningococcal Meningitis,Serogroup W-135, Meningococcal Meningitis,Serogroup W135, Meningococcal Meningitis,Serogroup Y, Meningococcal Meningitis,Meningococcal Meningitis,Meningococcal Meningitis, Serogroup W 135,Neisseria Meningitides,Serogroup W 135, Meningococcal Meningitis
D008586 Meningitis, Pneumococcal An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111) Meningitis, Streptococcus pneumoniae,Experimental Pneumococcal Meningitis,Meningitis, Pneumococcal, Experimental,Meningitis, Pneumococcal, Penicillin-Resistant,Meningitis, Pneumococcal, Recurrent,Experimental Pneumococcal Meningitides,Meningitides, Streptococcus pneumoniae,Meningitis, Experimental Pneumococcal,Pneumococcal Meningitides,Pneumococcal Meningitides, Experimental,Pneumococcal Meningitis,Pneumococcal Meningitis, Experimental,Streptococcus pneumoniae Meningitides,Streptococcus pneumoniae Meningitis
D009345 Neisseria meningitidis A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype. Diplokokkus intracellularis meningitidis,Meningococcus,Micrococcus intracellularis,Micrococcus meningitidis,Micrococcus meningitidis cerebrospinalis,Neisseria weichselbaumii
D010400 Penicillin G A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission. Benzylpenicillin,Benpen,Benzylpenicillin Potassium,Coliriocilina,Crystapen,Or-pen,Parcillin,Pekamin,Pengesod,Penibiot,Penicilina G Llorente,Penicillin G Jenapharm,Penicillin G Potassium,Penicillin G Sodium,Penicillin GrĂ¼nenthal,Penilevel,Peniroger,Pfizerpen,Sodiopen,Sodipen,Sodium Benzylpenicillin,Sodium Penicillin,Unicilina,Ursopen,Van-Pen-G
D002701 Chloramphenicol An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) Cloranfenicol,Kloramfenikol,Levomycetin,Amphenicol,Amphenicols,Chlornitromycin,Chlorocid,Chloromycetin,Detreomycin,Ophthochlor,Syntomycin
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

N I Girgis, and M W Yassin, and W R Sanborn, and R E Burdick, and H A el-Ela, and D C Kent, and K Sorensen, and I M Nabil
January 1988, Chemotherapy,
N I Girgis, and M W Yassin, and W R Sanborn, and R E Burdick, and H A el-Ela, and D C Kent, and K Sorensen, and I M Nabil
January 1987, Drugs under experimental and clinical research,
N I Girgis, and M W Yassin, and W R Sanborn, and R E Burdick, and H A el-Ela, and D C Kent, and K Sorensen, and I M Nabil
June 1983, Lancet (London, England),
N I Girgis, and M W Yassin, and W R Sanborn, and R E Burdick, and H A el-Ela, and D C Kent, and K Sorensen, and I M Nabil
October 1991, Lancet (London, England),
N I Girgis, and M W Yassin, and W R Sanborn, and R E Burdick, and H A el-Ela, and D C Kent, and K Sorensen, and I M Nabil
August 1984, The Journal of infectious diseases,
N I Girgis, and M W Yassin, and W R Sanborn, and R E Burdick, and H A el-Ela, and D C Kent, and K Sorensen, and I M Nabil
January 1969, Scandinavian journal of infectious diseases,
N I Girgis, and M W Yassin, and W R Sanborn, and R E Burdick, and H A el-Ela, and D C Kent, and K Sorensen, and I M Nabil
January 1988, Scandinavian journal of infectious diseases,
N I Girgis, and M W Yassin, and W R Sanborn, and R E Burdick, and H A el-Ela, and D C Kent, and K Sorensen, and I M Nabil
October 1982, Antimicrobial agents and chemotherapy,
N I Girgis, and M W Yassin, and W R Sanborn, and R E Burdick, and H A el-Ela, and D C Kent, and K Sorensen, and I M Nabil
October 1972, British medical journal,
N I Girgis, and M W Yassin, and W R Sanborn, and R E Burdick, and H A el-Ela, and D C Kent, and K Sorensen, and I M Nabil
September 1985, Lancet (London, England),
Copied contents to your clipboard!